Over 500,000 prescriptions of the XARELTO® vascular dose* and counting1

With extensive scientific support, the XARELTO® vascular dose* redefines treatment for patients with PAD and/or CAD2-4

The FIRST and ONLY treatment approach indicated to help reduce the risks of major CV events† in patients with CAD and major thrombotic vascular events‡ in patients with PAD, including patients after recent LER due to symptomatic PAD.2

The XARELTO® vascular dose* = XARELTO® 2.5 mg twice daily plus aspirin (75 mg to 100 mg) once daily.2

Efficacy and safety demonstrated by 2 landmark clinical trials that studied ~34,000 patients with CAD and/or PAD§3,4

CAD = coronary artery disease; CV = cardiovascular, LER = lower extremity revascularization; PAD = peripheral artery disease.

*XARELTO® 2.5 mg twice daily plus aspirin (100 mg in clinical trial; 75 mg to 100 mg in practice) once daily.
†Reduction of a composite of cardiovascular death, myocardial infarction, and stroke.
‡Reduction of a composite of myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology.
§Treatment schedule: XARELTO® 2.5 mg twice daily versus placebo; all patients received aspirin 100 mg once daily as background therapy.
IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.

CAD/PAD Resources

DOSING ACROSS INDICATIONS Condition-specific dosing for your patients

COMPASS REPRINT Eikelboom JW et al. Rivaroxaban with or without aspirin in chronic CV disease

CAD/PAD WELCOME KIT Your patient’s guide to starting treatment

View all resources

References: 1. Data on file. Janssen Pharmaceuticals, Inc. Data was sourced from IQVIATM, Real-World Evidence Claims Data [data period of October 2018-June 2021). 2. XARELTO® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 3. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization [article and supplementary appendix]. N Engl J Med. 2020;382(21):1994-2004. 4. Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS Trial: Net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation. 2020;142(1):40-48.